Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19

    NEXT STORY
    Ziopharm Oncology Announces Election of James Huang as Chairman of the Board of Directors
    PREV STORY
    Teladoc Health Issues Inaugural Corporate Social Responsibility Report
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Avant Diagnostics Announces Data Presentations at 2016 ASCO Annual Meeting

    SCOTTSDALE, Ariz. and GAITHERSBERG, Md., May 19, 2016 (GLOBE NEWSWIRE) -- Avant Diagnostics, Inc. ...

    author_avatar
    NASDAQ Market News

    Clinical Trial ‘Solutions’ Account for 40% of Global Spending on eCOA, eSource & Clinical Trials, Finds Fact.MR

    author_avatar
    NASDAQ Market News

    BioSig Latest Installation Broadens Clinical Footprint for its Signal Processing Technology for Electrophysiology

    author_avatar
    NASDAQ Market News